Evaluation of COVID-19 vaccine cost-effectiveness
The goal of this study is to evaluate the cost-effectiveness of a hypothetical vaccine to prevent COVID-19. As of July 2020, there were over 150 vaccine candidates in development with 6 in Phase III clinical trials. This study will project costs and health outcomes for a hypothetical vaccination program leveraging a simulation model previously developed by Dr. Prosser to evaluate the cost-effectiveness of the H1N1 vaccination program in 2009. The study will be led by SPH faculty members Dr. Lisa Prosser and Dr. David Hutton. The research team include doctoral and master’s students at HMP: Anton Avanceña, Dorian Ballard, Huey-Fen Chen, Grace Chung, Ellen Kim Deluca, Tran Doan, David Suh.